PNH与PNH-AA综合征异基因造血干细胞移植结局比较
该回顾性研究比较了46例接受allo-HSCT的PNH(16例)与PNH-AA综合征(30例)患者的结局。所有患者均成功植入,PNH组粒细胞和血小板植入中位时间均快于PNH-AA组,两组急性GVHD、慢性GVHD及感染发生率无显著差异,未发生早期死亡及复发。PNH组与PNH-AA组预期3年OS率分别为100.0%与(85.7±6.6)%(P=0.141),GFFS率分别为100.0%与(78.7±7.7)%(P=0.067)。
要点
- 所有46例患者均成功植入,无早期死亡及复发。
- PNH组粒细胞和血小板植入中位时间均快于PNH-AA组。
- 两组急性GVHD、慢性GVHD及感染发生率差异均无统计学意义。
核心结论
- allo-HSCT对PNH及PNH-AA综合征均有效,PNH组造血重建快于PNH-AA组,两组OS及GFFS率无差异。
研究设计与样本
- 回顾性分析2007年7月10日至2018年6月2日接受allo-HSCT的46例患者,其中PNH组16例,PNH-AA组30例。
主要发现
- PNH组与PNH-AA组回输单个核细胞中位数分别为10.58(3.83~13.83)×10^8/kg与10.81(3.96~33.40)×10^8/kg(P=0.668)。
- PNH组与PNH-AA组回输CD34+细胞中位数分别为5.00(3.14~8.42)×10^6/kg与3.57(1.97~6.17)×10^6/kg(P=0.002)。
- PNH组与PNH-AA组粒细胞植入中位时间分别为11(7~14)d与12(10~26)d(P=0.003),血小板植入中位时间分别为13(11~16)d与18(12~75)d(P=0.002)。
- 两组急性GVHD、慢性GVHD及移植过程中感染发生率差异均无统计学意义(P>0.05),未发生早期死亡及复发。
- PNH组与PNH-AA组预期3年OS率分别为100.0%与(85.7±6.6)%(P=0.141),GFFS率分别为100.0%与(78.7±7.7)%(P=0.067)。
关键数值与推荐
- 无关供者及单倍型移植预处理方案为白消安+环磷酰胺+兔抗人胸腺细胞球蛋白(ATG)。
- 同胞全相合移植预处理方案为氟达拉滨+环磷酰胺+ATG。
临床怎么用
- allo-HSCT可用于PNH及PNH-AA综合征患者,PNH组造血重建较快,两组生存结局无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH) with paroxysmal nocturnal hemoglobinuria-aplastic anemia (PNH-AA) syndrome. Methods: The outcomes of 46 patients who received allo-HSCT (16 PNH patients, 30 PNH-AA patients) from July 10, 2007 to June 2, 2018 were analyzed retrospectively. The conditioning regimen was busulfan, cyclophosphoramide, and ATG in haploidentical donors and unrelated donors. Patients with matched sibling donors were treated with the fludarabine, cyclophosphamide, and ATG regimen. Results: There were no differences of baseline data between the 2 groups except gender distribution and the numbers of haploidentical donor transplantation. The median values of absolute nucleated cell counts were 10.58 (3.83-13.83) ×10(8)/kg in the PNH group and 10.81 (3.96-33.40) ×10(8)/kg in the PNH-AA group (P=0.668) . The median doses of CD34(+) cells infused were 5.00 (3.14-8.42) ×10(6)/kg and 3.57 (1.97-6.17) ×10(6)/kg (P=0.002) , respectively. All patients obtained complete engraftment. The median time for myeloid engraftment were 11 (7-14) days in the PNH group and 12 (10-26) days in the PNH-AA group (P=0.003) . The median time for platelet engraftment were 13 (11-16) days and 18 (12-75) days (P=0.002) , respectively, after a median follow-up of 36 (4-132) months in the PNH group and 26 (4-75) months in the PNH-AA group (P=0.428) . There were no differences of incidence rates of acute graft-versus-host disease (aGVHD) , chronic GVHD and infection between PNH and PNH-AA groups (P>0.05) . No patient occurred early death and relapse. The estimated 3-year overall survival (OS) of PNH and PNH-AA groups were (100.0±0.0) % and (85.7± 6.6) % (P=0.141) , GVHD-free and failure-free survival (GFFS) were (100.0±0.0) %, (78.7±7.7) % (P=0.067) . Conclusions: allo-HSCT is effective for patients with PNH and PNH-AA syndrome. The preliminary results indicate that myeloid and platelet engraftment in PNH group were faster than PNH-AA group. There were no differences in OS and GFFS between PNH group and PNH-AA group. 目的: 比较异基因造血干细胞移植(allo-HSCT)治疗阵发性睡眠性血红蛋白尿症(PNH)与阵发性睡眠性血红蛋白尿症-再生障碍性贫血综合征(PNH-AA)的疗效。 方法: 对2007年7月10日至2018年6月2日期间接受allo-HSCT的46例PNH/PNH-AA患者进行回顾性分析。 结果: PNH-AA组(30例)女性比例及单倍型移植患者比例高于PNH组(16例),其他方面两组差异无统计学意义。无关供者移植及单倍型移植患者以白消安+环磷酰胺+兔抗人胸腺细胞球蛋白(ATG)方案进行预处理,同胞全相合移植患者以氟达拉滨+环磷酰胺+ATG方案进行预处理。PNH组、PNH-AA组回输单个核细胞分别为10.58(3.83~13.83)×10(8)/kg、10.81(3.96~33.40)×10(8)/kg(P=0.668),CD34(+)细胞分别为5.00(3.14~8.42)×10(6)/kg、3.57(1.97~6.17)×10(6)/kg(P=0.002)。所有患者均成功植入,PNH组、PNH-AA组粒细胞植入中位时间分别为11(7~14)d、12(10~26)d(P=0.003),血小板植入中位时间分别为13(11~16)d、18(12~75)d(P=0.002)。两组急性GVHD、慢性GVHD及移植过程中感染发生率差异均无统计学意义(P>0.05),未发生早期死亡及复发。PNH组、PNH-AA组预期3年总生存(OS)率分别为100.0%、(85.7±6.6)%(P=0.141),无移植物抗宿主病无失败生存(GFFS)率分别为100.0%、(78.7±7.7)%(P=0.067)。 结论: allo-HSCT对于PNH及PNH-AA均有较好疗效。PNH组造血重建快于PNH-AA组,OS及GFFS率无差异。.
引用
- Liu LM, Zhou HF, Wang QY, et al. [Outcomes of allogeneic hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria compared to paroxysmal nocturnal hemoglobinuria-aplastic anemia syndrome]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31340619. doi:10.3760/cma.j.issn.0253-2727.2019.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。